BioSpace News Archive

The plaintiffs allege that Gilead and other companies used anticompetitive tactics to keep prices artificially high for their respective HIV treatments.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Platform Provides Comprehensive Capabilities at Affordable Cost

Company scores high for having a culture of diversity & belonging and work-life balance

More than 12,000 buyers visit 2019 fair, up 8% on last year

Shanghai ChemPartner a leading global Contract Research Organization (CRO), along with Berkeley Lights, Inc. (BLI), the leader in digital cell biology, announced today they have taken the next important step in their collaboration.

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology Association (EHA), June 13-16 in Amsterdam.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), has been granted a new U.S. patent for a method of preventing or treating dry eye syndrome by administering Tβ4 with non-active ingredients to provide improved pharmacodynamics

The U.S. Food and Drug Administration today approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older.

Eisai today announced the presentation of new data and analyses in one oral presentation, 11 posters at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4 in Chicago.